+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07227870

Phase 2 Study of Weekly Intratumoral L19IL2L19TNF Injections for Patients with Locally Advanced Basal Cell Carcinoma Who Have Not Responded to or Cannot Tolerate Systemic Treatments

Led by Philogen S.p.A. · Updated on 2026-07-21

92

Participants Needed

18

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the activity and safety of intratumoral administration of combined L19IL2 and L19TNF in patients with locally advanced basal cell carcinoma BCC who have progressed on or cannot tolerate systemic therapies. This phase 2, open-label, single-arm study involves patients selected by a local multidisciplinary tumor board based on their disease status and treatment history. The trial aims to assess the best overall response rate up to 160 weeks after treatment begins, providing important information on this treatment approach for difficult-to-treat BCC cases. Participants will receive injections of L19IL2L19TNF directly into all injectable cutaneous, subcutaneous tumors, and nodal or in transit metastases once weekly for up to four weeks. Those with partial response or stable disease may receive a second four-week course of weekly injections at the physicians discretion. Each tumor will be measured at every treatment visit, and doses are adjusted based on tumor size, with a maximum dose specified for each visit. During the study, tumor assessments will occur at weeks 8 and 12 and then every eight weeks during the first year, followed by every 12 weeks in years two and three. Response confirmation involves tissue biopsy and independent central review. Patients will be monitored for overall survival through phone or documented contact every six months until death, withdrawal, or study completion. This comprehensive follow-up will continue for up to 160 weeks after starting treatment, ensuring detailed evaluation of treatment effects and patient outcomes.

CONDITIONS

Brief Title

L19IL2/TNF in Patients With Basal Cell Carcinoma

Research Team

L

Lisa Nadal

C

Concetta Aulicino

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here